Mirai Bio, a Cambridge, MA-based bioplatform innovation company, raised $50M in initial funding.
Flagship Pioneering made the founding investment.
The company intends to use the funds to further advance its platform to enhance and accelerate genetic medicine development across a wide range of therapeutic areas and modalities.
Led by CEO Geoffrey von Maltzahn, Mirai Bio has built an open platform driven by machine intelligence that solves the key limitations hindering genetic medicines, delivery, design, and manufacturing. Its machine intelligence-based, open platform unlocks delivery to any tissue and cell type through rapid, iterative learning of in vivo tested chemistries.
Mirai’s platform is enabled by high throughput automation and in vivo multiplexing, generating vast amounts of data that accelerate extensive optimization loops.
FinSMEs
27/09/2024